Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions

Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.

• Source: Alamy

Recent research highlights the importance of conducting clinical trials in more locations, showing that to truly improve diversity, regulators and sponsors must move beyond traditional tactics like modifying trial enrollment criteria or convincing underrepresented populations of the value of clinical research.

In fact, the research turns commonly thought truisms on their head: it appears that white people, not minorities, are most...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Brazil Looks To AI And Digital Technologies To Revitalize Clinical Research Environment

 

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

Survey Highlights Long Road Ahead For UK To Becoming Clinical Trials Hub

 

Commercial clinical trial sponsors have reported several challenges with setting up trials in the UK, which led the Health Research Authority and its partners to make “significant improvements,” to the process, a senior figure at the organization has said.

How England’s Cancer Vaccine Launch Pad Helped Scancell Speed Up Trial Patient Recruitment

 

As the CVLP prepares to support its third cancer vaccine trial, the Pink Sheet examined Scancell’s experience with the initiative, which the drug company used to recruit patients for its advanced melanoma vaccine trial.

New UK Network Targets Speed And Inclusion For Commercial Clinical Trials

 
• By 

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

More from R&D

New UK Network Targets Speed And Inclusion For Commercial Clinical Trials

 
• By 

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

Oncology: Plan Ahead To Rule Out Harm When Survival Not The Endpoint, US FDA Says

 

The FDA recommended sponsors plan ahead for potential issues if overall survival is not feasible as a primary or secondary efficacy endpoint in clinical trials and must be analyzed as a safety outcome.

Selective Safety Data Collection In Clinical Trials: Adoption Lags Despite Benefits, US FDA Says

 
• By 

Lack of awareness is limiting use of guidelines that simplify safety reporting for some late-stage trials, FDA says, while also highlighting wins. Boehringer experienced mixed results, while Novartis, Lilly, and Merck were more successful, and Roche should have probably tried, white paper suggests.